	Shopping Cart
Your cart contains 0 items : £0.00 ex shipping


Create an Account		Customer login

Flixotide Evohaler 50mcg

Price: only £6.53 (No VAT)
* Price shown per tablet / capsule.


	Key Points
		FREE SHIPPING ON THIS ITEM
		UK product supplied

Pack price equivalent (1 pack) is £6.53 (No VAT)

You must order the quantity stated on your prescription.

This product was added to our catalog on Saturday 10 December, 2011.

[+] Prescription Only Medicine - Click here for important information.

This product is a prescription-only medication (POM). You cannot order this item unless you have a valid prescription from a UK registered medical practitioner.

The original prescription must be posted to us before we can dispense this drug.

You may download our FREEPOST address label (PDF format) and print your envelope, which will be treated as first class post.

Alternatively, address your envelope:

Freepost RSEH-KURS-LLHY
Hordle Pharmacy
26 Ashley Lane
Hordle, Lymington
SO41 0GA

Note: If you hand write the address, the envelope will be treated as 2nd class post. For your convenience, we will send you a supply of pre-printed envelopes with your order.

Please order the exact quantity stated on your prescription.

There is no VAT on prescription-only medications for human use.

Don't have a prescription?

If you do not have a valid UK prescription, you may get one from PharmaDoctor. PharmaDoctor work with us to provide an online consultation service that may lead to the issue of a prescription. If successful, you pay a fee to PharmaDoctor that includes prescription issue and the cost of the medicines.

To use the PharmaDoctor service, simply click the red button above to be referred through to PharmaDoctor.

Product Details

Fluticasone propionate given by inhalation offers prophylactic treatment for asthma.

Adults:

Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis.

Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone.

Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. On introduction of inhaled fluticasone propionate many of these patients may be able to reduce significantly, or to eliminate, their requirement for oral corticosteroids.

Children:

Any child who requires prophylactic medication, including patients not controlled on currently available prophylactic medication.

Directions

Please take as instructed on your prescription. Please read the enclosed patient leaflet.

Warnings

Patients' inhaler technique should be checked regularly to make sure that inhaler actuation is synchronised with inspiration to ensure optimum delivery to the lungs. During inhalation, the patient should preferably sit or stand. The inhaler has been designed for use in a vertical position.

Flixotide Evohaler is not designed to relieve acute symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.

Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death. Increasing use of short-acting inhaled β2-agonists to relieve symptoms indicates deterioration of asthma control. If patients find that short-acting relief bronchodilator treatment becomes less effective, or they need more inhalations than usual, medical attention must be sought. In this situation patients should be reassessed and consideration given to the need for increased anti-inflammatory therapy (e.g. higher doses of inhaled corticosteroids or a course of oral corticosteroids). Severe exacerbations of asthma must be treated in the normal way.

There have been very rare reports of increases in blood glucose levels, in patients with or without a history of diabetes mellitus (See 4.8 'Undesirable Effects'). This should be considered in particular when prescribing to patients with a history of diabetes mellitus.

As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. Flixotide Evohaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important therefore that the dose of inhaled corticosteroid is reviewed regularly and reduced to the lowest dose at which effective control of asthma is maintained.

Pack Size

1 pack

More Info ..

To view this product's Patient Information Leaflet, click here.